Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide.

Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide. Abstract Text:

Keyvan , Lokiec,Isabelle Grandjean,Sophie Weill,Patricia de Cremoux,Vincent Bordier,Richard Ekue,Mickael Garcia,Marie-France Poupon,Didier Decaudin,Keyvan , Lokiec,Isabelle Grandjean,Sophie Weill,Patricia de Cremoux,Vincent Bordier,Richard Ekue,Mickael Garcia,Marie-France Poupon,Didier Decaudin,

BACKGROUND: Using a human small cell lung cancer (SCLC) xenografted in nude mice, we have previously reported enhanced tumor growth inhibition following chemotherapy in combination with imatinib (STI571). We therefore investigated the in vivo impact of imatinib on the pharmacokinetics and efficacy of chemotherapy. METHODS: Two different human tumors were used: SCLC6 small cell lung cancer xenografted in nude mice, and LY-3 EBV-associated human B-cell lymphoma xenografted in SCID mice. Plasma, urine, and fecal concentrations of etoposide (VP16) were determined by a validated high performance liquid chromatography method. Plasma concentrations of ifosfamidewere determined by a validated gas chromatography assay with nitrogen-phosphorus detection. RESULTS: Slight tumor growth inhibition was induced by imatinib administered alone in one in vivo EBV-associated B-cell lymphomatous xenograft. In contrast, an increase of the chemotherapy-induced antitumor effect was observed in the lymphoma model but not in a small cell lung cancer model when mice bearing human xenografted tumors were treated concomitantly by imatinib and chemotherapy. This antitumor effect was not influenced by concomitant administration of fluconazole. The AUC0-3 h (Area Under the concentration-time Curve) of etoposide was increased when mice were treated with etoposide + imatinib due to decreased fecal excretion. In contrast, imatinib did not appear to influence the urinary excretion of etoposide, and concomitant administration of the CYP3A4 inhibitor, fluconazole, with imatinib did not modify the pharmacokinetics of etoposide plus imatinib alone. CONCLUSION: Altogether, these results therefore justify further prospective phase I and II clinical trials with combinations of etoposide-based chemotherapy and imatinib in patients with certain cancers, such as malignant lymphoma, with careful toxicologic monitoring.

Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide. Publishing Authors By Initials

K ,F Lokiec,I Grandjean,S Weill,P de Cremoux,V Bordier,R Ekue,M Garcia,MF Poupon,D Decaudin,K ,F Lokiec,I Grandjean,S Weill,P de Cremoux,V Bordier,R Ekue,M Garcia,MF Poupon,D Decaudin,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: BMC pharmacology

VOLUME: 7

Page Numbers: 13

Journal Abbreviation: BMC Pharmacol.

ISSN: 1471-2210

DAY: 27

MONTH: 10

YEAR: 2007

Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100967806

Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide.

AFFILIATION: Department of Clinical Hematology, Institut Curie, Paris, France. k.rezai@stcloud-huguenin.org

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: BMC Pharmacol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide Related Publications

• A multicenter study of gemcitabine-containing regimen in relapsed or refractory Hodgkin's lymphoma patients.
• Imatinib mesylate reduces rituximab-induced tumor-growth inhibition in vivo on Epstein-Barr virus-associated human B-cell lymphoma.
• Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide.
• [A case of chronic atrophiant polychondritis.]
• [Atrophic chronic polychondritis.]
• [Ocular involvement revealing atrophic chronic polychondritis.]